HRPC(SH:600829) Shang Hai Zheng Quan Bao·2025-08-08 18:52Core Viewpoint - The company, Harbin Pharmaceutical Group Renmin Tongtai Pharmaceutical Co., Ltd., has conducted its second board meeting of the 11th session, approving several key proposals including the 2025 semi-annual report, accounts receivable factoring business, credit impairment loss provision, and the evaluation report of the "Quality Improvement, Efficiency Enhancement, and Return to Shareholders" action plan [4][6][8][24]. Company Overview - The company is a leading pharmaceutical distribution enterprise in Heilongjiang Province, focusing on four main business areas: pharmaceutical distribution, retail, medical services, and logistics [25]. - The company achieved a revenue of 5.149 billion yuan in the first half of 2025, representing a year-on-year growth of 3.29% [25]. Financial Data - The company plans to engage in accounts receivable factoring business with a total amount not exceeding 280 million yuan [15][18]. - The company recognized a credit impairment loss of 33,892,605.88 yuan for the first half of 2025 [20][22]. Board Meeting Decisions - The board meeting approved the semi-annual report and its summary, the proposal for accounts receivable factoring, and the credit impairment loss provision [4][6][8]. - All board members were present, and all proposals were passed unanimously [5][10]. Action Plan Evaluation - The company has implemented the "Quality Improvement, Efficiency Enhancement, and Return to Shareholders" action plan, focusing on enhancing its six core competencies [24][25]. - The company has made significant progress in governance, completing the board restructuring and enhancing the decision-making process [27][28]. Investor Relations Management - The company emphasizes investor relations management, ensuring effective communication and transparency with investors [29][30]. - The company has organized multiple investor meetings and responded to numerous inquiries to maintain open communication channels [29][30].